Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

677 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Applications of SGLT2 inhibitors beyond glycaemic control.
O'Hara DV, Lam CSP, McMurray JJV, Yi TW, Hocking S, Dawson J, Raichand S, Januszewski AS, Jardine MJ. O'Hara DV, et al. Among authors: lam csp. Nat Rev Nephrol. 2024 Aug;20(8):513-529. doi: 10.1038/s41581-024-00836-y. Epub 2024 Apr 26. Nat Rev Nephrol. 2024. PMID: 38671190 Review.
Microvascular Disease in Patients With Diabetes With Heart Failure and Reduced Ejection Versus Preserved Ejection Fraction.
Tromp J, Lim SL, Tay WT, Teng TK, Chandramouli C, Ouwerkerk W, Wander GS, Sawhney JPS, Yap J, MacDonald MR, Ling LH, Sattar N, McMurray JJV, Richards AM, Anand I, Lam CSP; ASIAN-HF Investigators. Tromp J, et al. Among authors: lam csp. Diabetes Care. 2019 Sep;42(9):1792-1799. doi: 10.2337/dc18-2515. Epub 2019 Jul 10. Diabetes Care. 2019. PMID: 31292141
The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program.
Arnott C, Neuen BL, Heerspink HJL, Figtree GA, Kosiborod M, Lam CS, Cannon CP, Rosenthal N, Shaw W, Mahaffey KW, Jardine MJ, Perkovic V, Neal B. Arnott C, et al. Int J Cardiol. 2020 Nov 1;318:126-129. doi: 10.1016/j.ijcard.2020.06.011. Epub 2020 Jun 20. Int J Cardiol. 2020. PMID: 32569700 Clinical Trial.
Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: A perspective based on the updated evidence.
Khunti K, Aroda VR, Bhatt DL, Bozkurt B, Buse JB, Heerspink HL, Inzucchi SE, Lam CSP, Marx N, McMurray JJV, Solomon SD, Kosiborod MN. Khunti K, et al. Among authors: lam csp. Diabetes Obes Metab. 2022 Nov;24(11):2071-2080. doi: 10.1111/dom.14805. Epub 2022 Aug 4. Diabetes Obes Metab. 2022. PMID: 35801339 Free article. Review.
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O'Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilderäng U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM; DELIVER Trial Committees and Investigators. Solomon SD, et al. Among authors: lam csp. N Engl J Med. 2022 Sep 22;387(12):1089-1098. doi: 10.1056/NEJMoa2206286. Epub 2022 Aug 27. N Engl J Med. 2022. PMID: 36027570 Free article. Clinical Trial.
Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial.
Butt JH, Jhund PS, Belohlávek J, de Boer RA, Chiang CE, Desai AS, Drożdż J, Hernandez AF, Inzucchi SE, Katova T, Kitakaze M, Kosiborod MN, Lam CSP, Maria Langkilde A, Lindholm D, Bachus E, Martinez F, Merkely B, Petersson M, Saraiva JFK, Shah SJ, Vaduganathan M, Vardeny O, Wilderäng U, Claggett BL, Solomon SD, McMurray JJV. Butt JH, et al. Among authors: lam csp. Circulation. 2022 Oct 18;146(16):1210-1224. doi: 10.1161/CIRCULATIONAHA.122.061754. Epub 2022 Aug 27. Circulation. 2022. PMID: 36029465 Free PMC article. Clinical Trial.
Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial.
Peikert A, Martinez FA, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Shah SJ, Katova T, Merkely B, Vardeny O, Wilderäng U, Lindholm D, Petersson M, Langkilde AM, McMurray JJV, Solomon SD. Peikert A, et al. Among authors: lam csp. Circ Heart Fail. 2022 Oct;15(10):e010080. doi: 10.1161/CIRCHEARTFAILURE.122.010080. Epub 2022 Aug 27. Circ Heart Fail. 2022. PMID: 36029467 Free article. Clinical Trial.
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER.
Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, Vaduganathan M, Gasparyan SB, Bengtsson O, Lindholm D, Petersson M, Langkilde AM, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Køber L, Lam CSP, Martinez FA, Sabatine MS, Shah SJ, Solomon SD, McMurray JJV. Jhund PS, et al. Among authors: lam csp. Nat Med. 2022 Sep;28(9):1956-1964. doi: 10.1038/s41591-022-01971-4. Epub 2022 Aug 27. Nat Med. 2022. PMID: 36030328 Free PMC article.
Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER.
Wang X, Vaduganathan M, Claggett BL, Hegde SM, Pabon M, Kulac IJ, Vardeny O, O'Meara E, Zieroth S, Katova T, McGrath MM, Pouleur AC, Jhund PS, Desai AS, Inzucchi SE, Kosiborod MN, de Boer RA, Kober L, Sabatine MS, Martinez FA, Ponikowski P, Shah SJ, Hernandez AF, Langkilde AM, McMurray JJV, Solomon SD, Lam CSP. Wang X, et al. Among authors: lam csp. Circulation. 2023 Feb 21;147(8):624-634. doi: 10.1161/CIRCULATIONAHA.122.062832. Epub 2022 Nov 7. Circulation. 2023. PMID: 36342789 Free PMC article.
677 results